You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

IMGN853

Showing 1 - 18 of 18
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Endometrial Cancer Trial in Boston, Worcester (Pembrolizumab, IMGN853)

Recruiting
  • Endometrial Cancer
  • Boston, Massachusetts
  • +2 more
Oct 24, 2022

Endometrial Cancer Trial in New Haven (IMGN853)

Recruiting
  • Endometrial Cancer
  • IMGN853
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 10, 2022

High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine, Carboplatin)

Not yet recruiting
  • High Grade Ovarian Cancer
  • +2 more
  • (no location specified)
Jul 11, 2022

Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Aurora (Mirvetuximab Soravtansine, Olaparib)

Not yet recruiting
  • Ovary Cancer
  • +2 more
  • Aurora, Colorado
    University of Colorado Hospital
May 30, 2023

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in China (Mirvetuximab Soravtansine)

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Bengbu, Anhui, China
  • +27 more
Nov 14, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Ovarian Cancer, Fallopian Tube, Primary Peritoneal Cancer Trial in Birmingham (mirvetuximab soravtansine (MIRV; IMGN853))

Recruiting
  • Ovarian Cancer
  • +2 more
  • mirvetuximab soravtansine (MIRV; IMGN853)
  • Birmingham, Alabama
    University of Alabama at Birmingham Womens & Infants Center
Jun 30, 2022

Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer Trial (Pegylated Liposomal Doxorubicin +

Not yet recruiting
  • Platinum-resistant Ovarian Cancer
  • +6 more
  • Pegylated Liposomal Doxorubicin + SL-172154
  • Mirvetuximab + SL-172154
  • (no location specified)
Jul 29, 2022

Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine,

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • +4 more
  • Birmingham, Alabama
  • +15 more
Dec 13, 2021

Tumors Trial in Canada, United States (Mirvetuximab soravtansine)

Completed
Has Results
  • Tumors
  • Mirvetuximab soravtansine
  • Fairway, Kansas
  • +11 more
Jan 27, 2021

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)

Recruiting
  • Ovarian Cancer
  • +2 more
  • Mirvetuximab soravtansine
  • Anchorage, Alaska
  • +55 more
Jul 25, 2022

Endometrial Cancer, Endometrial Adenocarcinoma, Endometrial Serous Adenocarcinoma Trial in Oklahoma City (Mirvetuximab

Withdrawn
  • Endometrial Cancer
  • +3 more
  • Oklahoma City, Oklahoma
    Stephenson Cancer Center
Jun 25, 2019

Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8

Completed
Has Results
  • Anatomic Stage II Breast Cancer AJCC v8
  • +20 more
  • Mirvetuximab Soravtansine
  • Houston, Texas
    M D Anderson Cancer Center
Nov 18, 2020

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine)

Completed
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • Phoenix, Arizona
  • +88 more
Jan 19, 2023

Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab Soravtansine, Paclitaxel,

Active, not recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • Mirvetuximab Soravtansine
  • +3 more
  • Birmingham, Alabama
  • +207 more
Oct 28, 2022

Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial (Mirvetuximab soravtansine plus Bevacizumab, Bevacizumab)

Recruiting
  • Ovarian Cancer
  • +2 more
  • New Orleans, Louisiana
  • +3 more
Dec 16, 2022

Breast Cancer Triple Negative Trial in Durham (Mirvetuximab Soravtansine (IMGN853))

Withdrawn
  • Breast Cancer Triple Negative
  • Mirvetuximab Soravtansine (IMGN853)
  • Durham, North Carolina
    Duke University Medical Center
Jul 2, 2018

Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine,

Completed
Has Results
  • Epithelial Ovarian Cancer
  • +3 more
  • Mirvetuximab soravtansine
  • +3 more
  • Birmingham, Alabama
  • +130 more
Sep 24, 2020